Abstract Number: 1118 • 2019 ACR/ARP Annual Meeting
US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation
Background/Purpose: To expand treatment options, increase access to life-saving medications, and lower healthcare costs through competition, the US Congress created an abbreviated licensure pathway for…Abstract Number: 1450 • 2017 ACR/ARHP Annual Meeting
Influence of Immunogenicity to the First Anti-TNF Therapy on Response to the Second Biologic Agent in RA Patients
Background/Purpose: There is currently no consensus on selecting a therapeutic target in patients (pts) non-responsive to their first TNF inhibitors (TNFi). The development of anti-drug…Abstract Number: 2477 • 2017 ACR/ARHP Annual Meeting
Descriptive Patterns of Switches and Swaps in Patients with Rheumatoid Arthritis Initially Treated with Anti-TNF Agents in First Intention between 2000 and 2006, and 2007 and 2015 – Experience from a Real-World Database RHUMADATA®
Background/Purpose: Between 2000 and 2006, the only other treatment option for patients with rheumatoid arthritis (RA) first exposed to an anti-TNF agent was another anti-TNF…Abstract Number: 2478 • 2017 ACR/ARHP Annual Meeting
Retention on Adalimumab, Etanercept, Golimumab and Infliximab in Two Eras – Experience of Patients with Rheumatoid Arthritis from a Real-World Database RHUMADATA®
Background/Purpose: Anti-TNFs have been used to treat RA since 2000. Since the availability of new agents with different mechanisms of action around 2007, the pattern…Abstract Number: 2487 • 2017 ACR/ARHP Annual Meeting
Comparison the Long-Term Clinical Outcomes between Non Anti-TNF Versus Anti-TNF in RA Patients Who Failed to a First Anti-TNF
Background/Purpose: There are many biological therapies for Rheumatoid Arthritis (RA) with different mechanisms of action and good efficacy rate; however, up to 40% of patients…Abstract Number: 2488 • 2017 ACR/ARHP Annual Meeting
Golimumab Retention Rate in Patients with Rheumatoid Arthritis. Predictors of Long-Term Retention
Background/Purpose: The efficacy of Golimumab (GLM) treatment in rheumatoid arthritis (RA) has been widely documented. The aim of this study was to analize the long-term…Abstract Number: 533 • 2016 ACR/ARHP Annual Meeting
What Proportion of Patients Fail to Achieve CDAI and SDAI Remission Based on Physician Global Assessment? an Analysis from the Prospective, Observational Registry
Background/Purpose: Physician’s Global Assessment of Disease Activity (MDGA) is a measure that is frequently incorporated in disease activity indices which reflects the physician’s perception of…Abstract Number: 612 • 2016 ACR/ARHP Annual Meeting
Long-Term Sustainability of TNF-Blocker Injection Spacing in Rheumatoid Arthritis: Results of a 3-Year Long-Term Observational Follow-up of a Tapering randomised Controlled Trial
Background/Purpose: Tapering of TNF blockers (TNFb) in rheumatoid arthritis (RA) patients in sustained remission is feasible in short-term randomized controlled trials (RCT). Less data are…Abstract Number: 625 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Intravenous Golimumab Plus Methotrexate in Patients 65 Years and Younger and Those Greater Than 65 Years of Age-a Post-Hoc Analysis
Background/Purpose: There is a paucity of data on the use of anti-TNF therapy in patients >65 years. In this sub-analysis of GO-FURTHER, we compare the…Abstract Number: 1043 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through Week 28
Background/Purpose: Subcutaneous (SC) golimumab (GLM) is currently approved for adult patients (pts) with RA, PsA, and AS. The GO-ALIVE study was designed to evaluate the…Abstract Number: 1453 • 2016 ACR/ARHP Annual Meeting
Treatment of BAFF Transgenic Mice with Anti-TNF: Monoclonals Are Associated with a Higher Risk of Lymphoma Than Etanercept
Background/Purpose: Patients suffering from rheumatoid arthritis (RA) have an increased risk of lymphoma and disease activity is the main risk factor. The impact of treatment,…Abstract Number: 2493 • 2016 ACR/ARHP Annual Meeting
Patient Characteristics and Medication Utilization Patterns of Infliximab-Treated Rheumatoid Arthritis Patients Subsequently Transitioned to Intravenous Golimumab
Background/Purpose: Infliximab (IFX) and golimumab (GLM-IV) for intravenous use are anti-TNF agents indicated for rheumatoid arthritis (RA) and differ in weight-based dose, induction schedule, and…Abstract Number: 2638 • 2016 ACR/ARHP Annual Meeting
In Vitro Expansion of Treg By Adaimumab Predicts Clinical Response to Therapy in Patients with Rheumatoid Arthritis
Background/Purpose: Regulatory T cells (Treg) are potent suppressors of immune responses and are considered a pivotal element in resolving inflammation and autoimmunity. We have previously…Abstract Number: 2780 • 2015 ACR/ARHP Annual Meeting
Relationship Between Immunogenicity, Hypersensitivity Reactions and Skin Tests Against Infliximab, Etanercept and Adalimumab in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Relationship between immunogenicity, hypersensitivity reactions and skin tests against Infliximab, Etanercept and Adalimumab in patients with rheumatoid arthritis and ankylosing spondylitis Background/Purpose: Anti-TNF drugs can…Abstract Number: 106 • 2015 ACR/ARHP Annual Meeting
Does the Timing of Phenotype Assessment Influence Association Results in Pharmacogenetics Studies of Anti-TNF Response in Rheumatoid Arthritis?
Background/Purpose: Pharmacogenetics studies of anti-tumor necrosis factor (TNF) response among patients with rheumatoid arthritis (RA) have routinely used assessment of response at a single time-point,…
ACR Meeting Abstracts